Join to view full profile
450 Brookline AveSmith 1058Boston, MA 02215
Phone+1 617-582-8598
Dr. Freedman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1998 - 2002
University of Pennsylvania Health SystemResidency, Internal Medicine, 1996 - 1998
University of Michigan Medical SchoolClass of 1996
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2011
Publications & Presentations
PubMed
- Polycomb Scaffolding Subunit EED Supports the SCLC Neuroendocrine Identity and EGFR-Mutant LUAD to SCLC Transformation.Yixiang Li, Yasmin N Laimon, Hyeonseo Cho, Marina Vivero, Gabriel Roberti de Oliveira
The Journal of Clinical Investigation. 2026-08-18 - Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.Elio Adib, Amin H Nassar, Sarah Abou Alaiwi, Sylvan C Baca, Timothy Hanlon
Molecular Cancer Research. 2026-06-03 - 3 citationsVascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer.Marco Campisi, Tatsuya Osaki, Ian Dryg, Carla Stornante, Jacqueline Wolff
Cancer Cell. 2026-04-13
Press Mentions
Prostate Cancer Metastasis Linked to Revival of Dormant Molecular ProgramJuly 19th, 2020
Grant Support
- Mapping the epigenetic dynamics of prostate cancer progression: integrating liquid biopsies and single-cell epigenomics for early detection of lineage plasticity and clinical decision-makingDANA-FARBER CANCER INST2025–2030
- Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
- Common biology underlying pleiotropic breast, prostate and ovarian cancer risk lociUNIVERSITY OF TEXAS HLTH SCIENCE CENTER2022–2027
- Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesDANA-FARBER CANCER INST2022–2027
- Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesDANA-FARBER CANCER INST2021–2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
